mianserin hydrochloride / Generic mfg. - LARVOL DELTA

Adjunctive Pharmacotherapy for Major Depressive Disorder with Anxiety Symptoms: from Monoamines to Recent Clinical Evidence. (PubMed, CNS Drugs) - "Reviewed treatments included atypical antipsychotics (aripiprazole, brexpiprazole, olanzapine, quetiapine XR, risperidone, cariprazine), bupropion, ketamine/esketamine, lithium, mirtazapine/mianserin, modafinil, and triiodothyronine...Aripiprazole, brexpiprazole, quetiapine XR, and ketamine/esketamine have been shown to improve depression and/or anxiety symptoms in patients with MDD with anxiety symptoms, although evidence is mainly short-term and derived from exploratory post hoc analyses of trials not designed to assess anxiety outcomes. Treatment decisions for patients with MDD with anxiety symptoms should be based on robust clinical data, and there is an unmet need for prospective clinical trials with anxiety-specific endpoints in this patient population."

Journal • Review • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Ameliorating calcium homeostasis improves longevity and healthspan in progeroid and naturally aged mice. (PubMed, Nat Commun) - "Mianserin (MIA), a tetracyclic antidepressant, attenuates senescence in cells derived from HGPS patients and naturally aging humans by antagonizing serotonin receptors HTR2B/2 C to lower Ca2+ concentrations. MIA also improves a range of aging phenotypes and significantly extends the lifespan of both LmnaG609G/G609G progeroid and naturally aging mice. Together, our findings uncover the mechanism of Ca2+ homeostasis disruption during premature and natural aging, and suggest MIA as a potential therapeutic strategy to extend healthy lifespan by augmenting Ca2+ homeostasis."

Journal • Preclinical • Targeted Protein Degradation • HTR2B • PARP1 • S100A6 • STING

From Relief to Risk: Antidepressants and Delirium — A Systematic Review and Meta-Analysis (APA 2026) - "Five studies suggested potential benefits of antidepressants: four trials showed that low-dose mianserin improved delirium symptoms in older inpatients without major adverse effects, and one retrospective study found trazodone effective in palliative care...In contrast, TCAs (OR = 1.52, 95% CI: 1.07–2.17), mianserin (OR = 1.67, 95% CI: 1.48–1.88), mirtazapine (OR = 1.32, 95% CI: 1.24–1.40), and particularly monoamine oxidase inhibitors (MAOIs) (OR = 2.88, 95% CI: 2.30–3.61) were significantly associated with a higher risk of delirium...In contrast, clinical trials have suggested symptomatic improvement. This inconsistency highlights the need for further research on mianserin's effect on delirium."

Retrospective data • Review • CNS Disorders

Storage stability of hospital-prepared mianserin suppositories: evaluation of residual active ingredient content and bacteriological contamination under different storage conditions. (PubMed, J Pharm Health Care Sci) - No abstract available

Journal

Contribution of the serotonergic system to myopia and the therapeutic effects of atropine and pirenzepine. (PubMed, Biomed Pharmacother) - "To investigate serotonergic signalling in experimental myopia, chicks undergoing FDM and LIM were treated with serotonergic antagonists (mianserin (2 nmoles) or methiothepin (1.5 nmoles))...Transcriptomic and biochemical analyses revealed widespread serotonergic signalling throughout the eye, limiting identification of a specific site of action. These findings suggest elevated serotonergic activity contribute to myopia progression and that muscarinic antagonists may exert their effects, at least in part, via modulation of serotonergic pathways."

Journal • Ophthalmology

Comparative acceptability of first-line antidepressants among older adults using filled prescription sequences: A nationwide cohort study. (PubMed, J Affect Disord) - "This large real-world study suggests differences in the acceptability of first-line antidepressants between older and younger patients. Although escitalopram ranked first regardless of age, alpha-2 blockers (mianserin and mirtazapine) emerged as acceptable options in older patients only."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Analgesic Efficacy and Tolerability of Amitriptyline versus Mianserin in Chronic Low Back Pain: A Randomised, Double-Blind, Controlled Pilot Trial. (PubMed, J Pain Res) - "Both amitriptyline and mianserin appear to provide comparable adjunctive efficacy for CLBP. Mianserin may be more tolerable and cost-effective in resource-limited settings, although it is not yet approved for pain indications."

Clinical • Journal • Back Pain • Lumbar Back Pain • Mood Disorders • Musculoskeletal Pain • Pain • Psychiatry

Validation in Drosophila of the in silico predicted clomipramine as repurposable for SOD1-ALS. (PubMed, Neurotherapeutics) - "Current Food and Drug Administration-approved drugs -riluzole, edaravone, and tofersen - offer limited clinical benefit due to ALS multifactorial etiology and high heterogeneity...Leveraging the SAveRUNNER algorithm, we identified several potentially repurposable candidates, including clomipramine (Anafranil®), mianserin (Lantanon®/Tolvon®), and modafinil (Provigil®)...Our results demonstrate that clomipramine is the most promising candidate, ameliorating lifespan reduction, improving climbing abilities, and mitigating both genomic instability and inflammation, key pathological hallmarks of these SOD1-ALS models. Despite needing further validation in higher organisms, our Drosophila findings represent preliminary yet significant support for clomipramine's action as an add-on treatment for SOD1-ALS."

Journal • Amyotrophic Lateral Sclerosis • CNS Disorders • Inflammation • Respiratory Diseases

From REM Sleep behavior disorder to Parkinson's Disease: a case report tracing the evolution from parasomnia to neurodegeneration (ECNP 2025) - "Initial pharmacological management with mianserin was ineffective, whereas clonazepam provided partial symptom relief—consistent with its known efficacy in managing RBD symptoms. Its identification, particularly in older adults, should prompt clinicians to monitor for early signs of neurodegeneration and consider referral to neurology for ongoing assessment. Early diagnosis of Parkinson's disease offers potential benefits in terms of treatment planning, patient counseling, and inclusion in neuroprotective trials."

Case report • Clinical • Alzheimer's Disease • CNS Disorders • Dementia • Lewy Body Disease • Mental Retardation • Movement Disorders • Multiple System Atrophy • Parkinson's Disease • Psychiatry • REM Sleep Behavior Disorder • Sleep Disorder

Redressing long-term antidepressant use in general practice (RELEASE) (ECNP 2025) - "Antidepressants include selective serotonin reuptake inhibitors (sertraline, escitalopram fluoxetine, paroxetine, fluvoxamine and citalopram); serotonin and norepinephrine reuptake inhibitors (venlafaxine, desvenlafaxine, duloxetine); and other antidepressants (mirtazapine, vortioxetine, mianserin, moclobemide, reboxetine, agomelatine). 26 practices and 485 participants randomised. Data collection complete November 2025. Implications: This study will develop new knowledge applicable internationally on the effectiveness, cost-effectiveness, and implementation of the RELEASE multi-strategy intervention in prompting review of antidepressant medication and supporting informed decision-making and safe cessation via hyperbolic tapering to minimise withdrawal symptoms to improve primary mental health care and outcomes for patients."

Alzheimer's Disease • CNS Disorders • Dementia • Mood Disorders • Neuralgia • Psychiatry

Response probability to single intravenous racemic ketamine with psychopharmacological combinations: a pooled post-hoc study (ECNP 2025) - "The combination of ketamine with antidepressants that block 5-HT2A receptors (such as mirtazapine, mianserine, trazodone, and agomelatine; n = 41) significantly increased the response rate to 58.5%, compared to 28.9% in those who did not receive these combinations. In contrast, combining ketamine with serotonin reuptake inhibitors (escitalopram, fluoxetine, paroxetine, sertraline, vortioxetine; n = 34) or with antipsychotics characterized by higher D2 than 5-HT2A blockade (amisulpride, aripiprazole, cariprazine; n = 10) significantly reduced the response rate to 26.5% and 0%, respectively, compared to 53.8% and 48.7% in those not receiving these combinations. Combination of ketamine with serotonin and norepinephrine reuptake inhibitors (clomipramine, venlafaxine, duloxetine, milnacipran; n = 30) or with antipsychotics (n = 40), compared to ketamine without SNRIs or without antipsychotics, did not significantly alter the probability of response (p = 0.369 and p = 0.083,..."

Retrospective data • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Utilization of psychotropic drugs in Serbia from 2006 to 2021: Patterns before and during the COVID-19 pandemic. (PubMed, PLoS One) - "The COVID-19 pandemic did not contribute to change in consumption of psychotropic drugs in Serbia. Still, the use of antidepressants, atypical antipsychotics, anxiolytics, sedatives, hypnotics, anti-dementia drugs and gabapentinoids increased from 2006 to 2021."

Journal • Alzheimer's Disease • CNS Disorders • Dementia • Infectious Disease • Mental Retardation • Novel Coronavirus Disease • Psychiatry

Berberine-Induced Behavioral Effects on Tail Suspension Test, BDNF, and CREB Levels in the Prefrontal Cortex, Hippocampus, and Amygdala: Modulation by Central Serotonergic Transmission. (PubMed, Synapse) - "Preinjection with the 5-HT precursor, 5-hydroxytryptophan (5-HTP; 50 and 100 µg/mouse, intracerebroventricular [i.c.v.]), and the selective serotonin reuptake inhibitor (SSRI), fluoxetine (5 and 10 mg/kg, i.p.), enhanced the berberine-induced antidepressant-like effect, whereas it was reversed in mice pretreated with 5-HT1A receptor agonist, 8-hydroxy-2(-dipropylamino)tetralinhydrobromide (8-OH-DPAT) (0.01 and 0.1 µg/mouse, i.c.v.), or the 5-HT2A/2C receptor antagonist, mianserin (1, 1.5 µg/mouse, i.c.v.). These findings suggest that serotonergic transmission modulates the antidepressant-like activity and the BDNF/CREB alterations induced by berberine, likely through a mechanism mediated by 5-HT1A and 5-HT2A/2C receptors. This study underscores the role of serotonergic transmission in the effects induced by berberine."

Journal • BDNF

Evaluation of various internal standards for quantification of dextromethorphan and diphenhydramine in plasma: a fatal overdose case of a mid-teenager caused by personally imported and over-the-counter medicines. (PubMed, Forensic Toxicol) - "The concentrations of both drugs in plasma samples were estimated to cause death. When using an alternative IS, a validation study is needed to select the optimal IS."

Journal

Environmental Antidepressants Disrupt Metabolic Pathways in Spirostomum ambiguum and Daphnia magna: Insights from LC-MS-Based Metabolomics. (PubMed, Molecules) - "Pharmaceuticals such as fluoxetine, paroxetine, sertraline, and mianserin occur in aquatic environments at low yet persistent concentrations due to their incomplete removal in wastewater treatment plants. They also underscore the considerable potential of metabolomics as a powerful and sensitive tool for ecotoxicological risk assessments, particularly when applied across multiple model organisms to capture interspecies variations. However, further research is essential to identify which specific pathway disruptions are most predictive of adverse effects on organismal health."

Journal • Metabolic Disorders

Enhanced inhibitory effects of mianserin in combination with sorafenib on liver cancer growth through targeting the CCR9-AKT pathway. (PubMed, Am J Cancer Res) - "This study is the first to demonstrated that mianserin effectively limits the growth of liver cancer by downregulating CCR9, in turn, inactivating the AKT-(β-catenin/NFκB) pathway. Both in vitro and in vivo experiments highlight mianserin's potential as an adjuvant therapy to sorafenib, offering a promising strategy to overcome current challenges in liver cancer treatment."

Journal • Liver Cancer • Oncology • Solid Tumor • HSPD1

Association of Medication Use and 8-Year Mortality Risk in Patients With Parkinson Disease: Drug-Wide Trial Emulation. (PubMed, Neurology) - "Our study identified several drugs with potential disease-modifying properties that could be candidates for future clinical trials. It highlights the potential of repurposing existing medications to advance drug development. While these findings are exploratory and, therefore, insufficient to justify immediate clinical application, they warrant further investigation and potential inclusion in clinical trials."

Journal • Observational data • CNS Disorders • Cough • Erectile Dysfunction • Infectious Disease • Movement Disorders • Ophthalmology • Pain • Parkinson's Disease • Respiratory Diseases

Antidepressant Therapy and Depression Disorder. (PubMed, Pril (Makedon Akad Nauk Umet Odd Med Nauki)) - "Research highlights the importance of combining selective serotonin reuptake inhibitors (SSRIs) with antidepressants that act as antagonists of presynaptic α2-autoreceptors and α2-heteroreceptors, such as Mianserin, Trazodone, and Mirtazapine. Aim: to evaluate the effectiveness of combined therapy using Mirtazapine (α2-autoreceptor antagonist) and Sertraline (serotonin reuptake inhibitor) in treating depression...Additionally, the difference in HRS scores between one-month and three-month treatment periods was also significant (Z = -4.717, P ≤ 0.001). The results of our study demonstrate that initiating combined antidepressant therapy at the outset of treatment is highly effective."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry • Sexual Disorders

An Overview of the Systematic Reviews About the Efficacy of Fluvoxamine on Depression. (PubMed, Pharmaceuticals (Basel)) - "Comparisons with imipramine, clomipramine, amitriptyline, dothiepin, paroxetine, fluoxetine, citalopram, mianserin, nortriptyline, and moclobemide generally revealed no significant differences in efficacy. However, some reviews indicated that venlafaxine and mirtazapine were superior to fluvoxamine in certain outcomes, while fluvoxamine demonstrated greater efficacy than desipramine in one review. Sertraline and milnacipran showed mixed or review-quality-dependent results, with one low-quality review favoring milnacipran...While no single antidepressant was universally superior, fluvoxamine's unique pharmacological profile and favourable safety characteristics support its clinical utility. Further research is needed to explore its role in personalized treatment strategies and emerging therapeutic contexts, such as comorbid anxiety and post-traumatic stress disorder."

Journal • Review • CNS Disorders • Depression • Mental Retardation • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry

Electroconvulsive Therapy and the Onset of Diabetes: A Rare but Critical Complication in Children (ESPE-ESE 2025) - "Case Presentation A 13-year-old boy with early-onset psychosis and treatment-resistant ADHD had been on medication, including fluoxetine, olanzapine, quetiapine, and mianserin for the past two months. Conclusion Considering the uncertainty surrounding the etiology of childhood psychiatric disorders and the potential impact of ECT on glycemic control,the effect of ECT on beta cell reserve in children should be further evaluated. A multidisciplinary approach is essential during the ECT treatment process in children, with careful attention to hyperglycemic complications and more frequent monitoring of blood glucose levels."

Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Diabetes • Infectious Disease • Measles • Mental Retardation • Metabolic Disorders • Ocular Inflammation • Ophthalmology • Pediatrics • Psychiatry

Treatment with antidepressant drugs and hyponatremia: a network meta-analysis. (PubMed, J Endocrinol Invest) - "These data appear useful on clinical grounds, in order to increase the awareness regarding the possibility that antidepressants induce hyponatremia and to encourage regular serum sodium monitoring."

Journal • Retrospective data • Review • Cardiovascular • Heart Failure

Efficacy and tolerability of antidepressants in individuals suffering from physical conditions and depressive disorders: network meta-analysis. (PubMed, Br J Psychiatry) - "Antidepressants are effective in individuals with comorbid physical conditions, although tolerability is a relevant concern. Selective serotonin reuptake inhibitors (SSRIs) have the best benefit-risk profile, making them suitable as first-line treatments, while tricyclics are highly effective but less tolerated than SSRIs and placebo."

Journal • Retrospective data • Review • CNS Disorders • Depression • Mood Disorders • Psychiatry

High-performance liquid chromatography-tandem mass spectrometry for simultaneous determination of 23 antidepressants and active metabolites in human serum and its application in therapeutic drug monitoring. (PubMed, Front Pharmacol) - "In this paper, we developed a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method to study simultaneously TDM and clinical pharmacokinetics of 23 antidepressants and active metabolites: sertraline, escitalopram, fluvoxamine, paroxetine, duloxetine, milnacipran, fluoxetine, venlafaxine, O-desmethylvenlafaxine, mirtazapine, trazodone, bupropion, hydroxybupropione, norfluoxetine, vortioxetine, agomelatine, mianserin, doxepine, desmethyldoxepin, clomipramine, desmethylclomipramine, amitriptyline and nortriptyline hydrochloride...Validation of the developed method was carried out based on the Chinese Pharmacopoeia guidelines for bioanalytical method validation, including assessment of specificity, calibration curves, carryover, accuracy, crosstalk, precision, stability, recovery, dilution integrity and matrix effect. The results showed that a simple, fast, reliable and specific HPLC'MS/MS method was developed and validated, and all the..."

Journal • CNS Disorders • Depression • Psychiatry

Association Between CYP2D6 Genotypes and Serum Concentrations of Mirtazapine and Mianserin. (PubMed, Basic Clin Pharmacol Toxicol) - "In conclusion, CYP2D6 genotype was only associated with a minor change in mirtazapine serum concentration. The association between CYP2D6 genotype and mianserin serum concentration was greater, with 80% higher mianserin C/D ratio in CYP2D6 PMs compared with NMs."

Journal • Retrospective data

A New Trick of Old Dogs: Can Kappa Opioid Receptor Antagonist Properties of Antidepressants Assist in Treating Treatment-Resistant Depression (TRD)? (PubMed, Pharmaceuticals (Basel)) - " The antidepressants mianserin and mirtazapine (separately) induced dose-dependent antinociception, each yielding a biphasic dose-response curve. Similarly, the antidepressant venlafaxine produced a potent effect and reboxetine produced a weak effect. The antipsychotics risperidone and amisulpride exhibited a dose-dependent antinociceptive effect... Clinical studies are mandatory to establish the potential efficacy of augmentation of the treatment with antidepressants with these drugs in persons with treatment-resistant depression and the optimal dosage of medications prescribed. We suggest a possible beneficial effect of antidepressants with kappa antagonistic properties."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry